---
title: "Wedbush Sticks to Their Buy Rating for Immunome (IMNM)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295680062.md"
description: "Wedbush analyst maintained a Buy rating on Immunome today and set a price target of $35.00.Claim 55% Off TipRanks Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks Currently, the analyst consensus on Immunome is a Strong Buy with an average price target of $36.00."
datetime: "2026-08-12T14:05:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295680062.md)
  - [en](https://longbridge.com/en/news/295680062.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295680062.md)
generator: "portal-rs"
---

# Wedbush Sticks to Their Buy Rating for Immunome (IMNM)

Wedbush analyst maintained a Buy rating on Immunome today and set a price target of $35.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Currently, the analyst consensus on Immunome is a Strong Buy with an average price target of $36.00.

### Related Stocks

- [IMNM.US](https://longbridge.com/en/quote/IMNM.US.md)

## Related News & Research

- [Immunome - Enters Amendment No. 4 To License Agreement With Bristol-Myers Squibb Company On Oct 2, 2026](https://longbridge.com/en/news/300933270.md)
- [Immunome issues 4,425,487 shares to Bristol-Myers Squibb in unregistered sale](https://longbridge.com/en/news/300932531.md)
- [Immunome Restructures BMS Deal, Gains Key Patent Rights](https://longbridge.com/en/news/300936952.md)
- [Immunome's IM-1340 Receives FDA IND Clearance For Advanced Solid Tumors](https://longbridge.com/en/news/300570999.md)
- [Immunome (NASDAQ:IMNM) Coverage Initiated by Analysts at Alliance Global Partners](https://longbridge.com/en/news/299646619.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**